- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody
-
- Kitagawa Satoshi
- Department of Neurology, Keio University School of Medicine
-
- Osada Takashi
- Department of Neurology, Keio University School of Medicine
-
- Kaneko Kimihiko
- Department of Neurology, Tohoku University Graduate School of Medicine Department of Neurology, National Hospital Organization Miyagi Hospital
-
- Takahashi Toshiyuki
- Department of Neurology, Tohoku University Graduate School of Medicine Department of Neurology, National Hospital Organization Yonezawa Hospital
-
- Suzuki Norihiro
- Department of Neurology, Keio University School of Medicine Department of Neurology, Shonan Keiiku Hospital
-
- Nakahara Jin
- Department of Neurology, Keio University School of Medicine
Bibliographic Information
- Other Title
-
- “視神経脊髄型多発性硬化症”を疑う病態から抗ミエリンオリゴデンドロサイト糖蛋白質抗体を検出した場合の臨床的検討
Search this article
Description
<p>We report an 18 year-old-male, who had been aware of decreased visual acuity for 6 months, newly presented with paresis and sensory disturbance in his right leg. On admission, his critical flicker frequency was reduced bilaterally, and his spinal cord MRI revealed T2-hyperintense lesions in cervical and thoracic cord with occasional contrast enhancements, but none of them were longitudinally extensive. There was no evidence of T2-hyperintense in his brain MRI. Anti-aquapolin-4 (AQP4) antibody was negative but the patient was positive for oligoclonal bands in his cerebrospinal fluid. The patient was tentatively diagnosed as opticospinal multiple sclerosis (OSMS). However, he later tuned out to be positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibody. The 2017 revised McDonald criteria don’t take anti-MOG antibody into account in detail as to how clinicians should deal with patients fulfilling the MS criteria when they were also positive for anti-MOG antibody, because of its difficult problem of independence. So, we need to accumulate knowledge about these cases.</p>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 58 (12), 737-744, 2018
Societas Neurologica Japonica
